{"entity":{"id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of Rezvilutamide, Tazemetostat in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer is a phase 1/2 interventional study registered as NCT07407283 by Jiangsu HengRui Medicine Co., Ltd., with 100 participants planned, started 2026-04-08 and due to reach its primary completion in 2027-11. Interventions recorded: SHR-4394, Rezvilutamide, HRS-5041 Tablets, Tazemetostat. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07407283","url":"https://clinicaltrials.gov/study/NCT07407283"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["rezvilutamide","tazemetostat"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07407283","phase":"1/2","setting":"A Multicenter, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct07407283/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/"},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}